Wantstats Reports Company List - Profiles & Intelligence

Vertex is the world's dominant cystic fibrosis franchise owner and, increasingly, a diversified specialty biotechnology platform. Its economic engine is a near-monopoly in CFTR modulation — five approved medicines treating roughly 95 percent of people with CF in core markets, generating over $11.1 billion of FY2025 revenue at 86 percent gross margin and effectively no branded competition until the late 2030s. Around that annuity, management has assembled four additional growth pillars: hematology (CASGEVY, the first approved CRISPR/Cas9 therapy), acute pain (JOURNAVX, the first new non-opioid analgesic mechanism in decades), nephrology (povetacicept, PDUFA 30 November 2026; inaxaplin behind it), and — following the $10.0 billion Crinetics acquisition completed 1 September 2026 — rare endocrinology. Vertex is unusual among large-cap biotechs in combining double-digit organic revenue growth, 40 percent-plus non-GAAP operating margins, a net cash balance sheet, and no dividend. The central investment question is whether the non-CF pillars scale before CF growth mathematically decelerates. *FY2025 is verified from the FY2025 Form 10-K. --- ### The company's own characterisation From the FY2025 Form 10-K, Item 1: Vertex describes itself as "a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets." It states approved medicines for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, with mid- and late-stage clinical programmes across IgA nephropathy, APOL1-mediated kidney disease, neuropathic pain, type 1 diabetes, primary membranous nephropathy, autosomal dominant polycystic kidney disease and myotonic dystrophy type 1. The stated core strategy is "to discover, develop, and commercialize innovative medicines by combining transformative advances in the understanding of human disease and the science of therapeutics." Management identifies five selection filters for programmes: disease areas with known causal human biology; targets validated by causal human biology; predictive lab assays and clinical biomarkers; potential for transformative benefit regardless of modality; and an efficient path to registration and approval. The company repeatedly uses the term "serial innovation" — advancing multiple compounds per target so that first-in-class assets are followed by internally generated best-in-class successors. ### Independent characterisation Vertex is best understood as a causal-biology franchise operator rather than a conventional diversified pharmaceutical company. Three structural features distinguish it: **A single-product-family concentration with monopoly economics.** In FY2025, TRIKAFTA/KAFTRIO alone contributed $10.31 billion, or 85.9 percent of total revenue. Adding ALYFTREK ($837.8 million) and the legacy CF portfolio ($644.7 million) puts cystic fibrosis at $11.80 billion, or 98.3 percent of total revenue. No competitor markets an approved CFTR modulator. Vertex is therefore not competing on price or share within its core market; it is competing against the natural ceiling of a fixed genetic patient population (approximately 112,000 people in target markets, of whom roughly three quarters are already treated). **A specialty, not primary-care, commercial model.** The company sells primarily to a limited number of specialty pharmacies and specialty distributors, plus certain major U.S. wholesalers; outside the U.S. it sells largely through distributors, retail pharmacies and government-owned or supported hospitals and clinics. CASGEVY is sold in certain markets directly to authorised treatment centres. This model supports very low SG&A intensity relative to peers — SG&A was 14.6 percent of revenue in FY2025 even in a triple-launch year — and management explicitly reiterates a "commitment to specialty model" in investor materials. **A modality-agnostic R&D engine.** Vertex has now delivered approved products across small molecules (CFTR modulators, JOURNAVX), ex vivo CRISPR/Cas9 gene editing (CASGEVY), and is in pivotal development with a biologic (povetacicept, a BAFF/APRIL dual inhibitor) and a stem cell-derived cell therapy (zimislecel). Post-Crinetics it adds a GPCR-focused small molecule endocrinology platform. ### Revenue model Vertex's revenue is essentially 100 percent product revenue. In FY2025, product revenues net were $11,970.6 million of $12,001.3 million total revenue; the residual $30.7 million of "other revenues" reflects out-licensing consideration (principally the 2025 Zai Lab and Ono povetacicept agreements for Asian territories). There is no meaningful service, subscription or device revenue. Royalty and milestone income is de minimis on the inbound side and Vertex is a net payer of royalties — notably to the Cystic Fibrosis Foundation under the 2004 CFF Agreement (tiered single-digit to sub-teens royalties on ivacaftor, lumacaftor and tezacaftor; low-to-mid single digits on elexacaftor; no royalty on compounds first synthesised and tested on or after 1 September 2016, which importantly means vanzacaftor and deutivacaftor in ALYFTREK carry lower royalty burden). CASGEVY is economically distinct: under the amended and restated joint development and commercialisation agreement with CRISPR Therapeutics AG, net profits and losses are allocated 60 percent to Vertex and 40 percent to CRISPR, with Vertex leading global development, manufacturing and commercialisation. ### Value chain position Vertex occupies the discovery-through-commercialisation span but is deliberately asset-light in manufacturing. It maintains internal small molecule manufacturing in Boston (used for clinical and certain commercial TRIKAFTA/KAFTRIO steps) and internal cell therapy manufacturing capability in the Boston area, but relies on a global third-party network — including contract manufacturers based in China — for the majority of commercial supply, with second sources maintained for the vast majority of commercial products including active ingredients, drug product and finished dosage packaging. A strategic agreement with Lonza supports T1D cell therapy manufacture. ### Customers and end-markets Direct customers: specialty pharmacies, specialty distributors, wholesalers, hospitals, clinics, authorised treatment centres, and government-owned or supported purchasers outside the U.S. Economic customers: national payors and reimbursement authorities (NHS England, AIFA, G-BA/GKV, HAS, PBAC, pCPA), U.S. commercial payors, the three national U.S. pharmacy benefit managers, state Medicaid programmes, Medicare Part D plans, and Gulf state health ministries. End-markets served as of the report date: cystic fibrosis; severe sickle cell disease; transfusion-dependent beta thalassemia; moderate-to-severe acute pain; and — from 1 September 2026 — acromegaly (PALSONIFY). Near-term addressable: IgA nephropathy (PDUFA 30 November 2026).

Deep Intelligence Across Industries

Cotiviti, Inc.

Medeanalytics, Inc.

Bridgepoint Group Plc.

Fun Factory Gmbh

What our clients say

Lifestyles

Doc Johnson Enterprises

Lovehoney Group

BMS Factory

Lelo

C.R Bard, Inc

Vertex Pharmaceuticals

Candela Corporation

Invivoscribe, Inc.

NG Biotech

Foundation Medicine, Inc.

ArcherDX, Inc.

Ortho Clinical Diagnostics

AUTOBIO

FUJIREBIO

MINDRAY

Bluebird Botanicals LTD

ENDOCA

Elixinol Global Limited

CBD American Shaman

Ziehm Imaging GmbH

OrthoScan, Inc.

Truven Health Analytics

Quantros Inc

MEDISOLV INC

ENLI HEALTH INTELLIGENCE